Bright Minds Biosciences (DRUG) Cost of Revenue (2020 - 2026)
Bright Minds Biosciences' (DRUG) quarterly Cost of Revenue came in at $30978.8 in Q1 2026, down 60.61% YoY from $78639.4 in Q1 2025, and down 71.99% on a QoQ basis from $110585.5 in Q4 2025.
Powered by 
Analysis
Bright Minds Biosciences (DRUG) Cost of Revenue (2020 - 2026) Analysis & Trends
Bright Minds Biosciences (DRUG) has 7 years of Cost of Revenue data on file, last reported at $30978.8 in Q1 2026.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cost of Rev (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.26 Bn | 131.41 Bn | 2.84 Bn | 489.20 Mn |
| 2 | Regeneron Pharmaceuticals | 85.64 Bn | 77.64 Bn | 3.93 Bn | 360.70 Mn |
| 3 | Argenx Se | 63.46 Bn | 58.27 Bn | 1.37 Bn | 145.00 Mn |
| 4 | Moderna | 57.83 Bn | 52.69 Bn | 52.00 Mn | 93.00 Mn |
| 5 | Revolution Medicines | 44.08 Bn | 44.08 Bn | - | - |
| 6 | BeOne Medicines | 39.94 Bn | 34.84 Bn | 1.53 Bn | 174.53 Mn |
| 7 | Alnylam Pharmaceuticals | 35.19 Bn | 31.88 Bn | 992.69 Mn | 298.26 Mn |
| 8 | Royalty Pharma | 28.42 Bn | 27.58 Bn | - | - |
| 9 | Insmed | 27.35 Bn | 26.19 Bn | 358.27 Mn | 67.21 Mn |
| 10 | Bright Minds Biosciences | 460.55 Mn | 238.02 Mn | - | 20,126.96 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 20,126.96 |
| Mar 31, 2026 | 30,978.85 |
| Dec 31, 2025 | 110,585.46 |
| Sep 30, 2025 | 90,053.33 |
| Jun 30, 2025 | 9,035.84 |
| Mar 31, 2025 | 78,639.36 |
| Dec 31, 2024 | 27,456.39 |
| Sep 30, 2024 | 17,771.41 |
| Jun 30, 2024 | 8,307.95 |
| Mar 31, 2024 | 66,261.06 |
| Dec 31, 2023 | 53,101.78 |
| Sep 30, 2023 | 26,445.47 |
| Jun 30, 2023 | 12,794.16 |
| Mar 31, 2023 | 68,856.86 |
| Dec 31, 2022 | 30,148.83 |
| Sep 30, 2022 | 29,995.11 |
| Jun 30, 2022 | 6,282.57 |
| Mar 31, 2022 | 73,823.06 |
| Dec 31, 2021 | 81,269.35 |
| Sep 30, 2021 | 10,722.14 |